Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations (NASDAQ:CELC)March 26, 2026
Share Facebook Twitter LinkedIn Pinterest Email Yara International Non-GAAP EPS of $1.01, revenue of $3.65B
Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations (NASDAQ:CELC)March 26, 2026
Marchex anticipates 10% revenue growth run rate in 2026 while accelerating AI-driven bundled solutions (NASDAQ:MCHX)March 25, 2026
